LINCOLN — LINCOLN PHARMACEUTICALS Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹12.31bn
- IN₹9.94bn
- IN₹6.71bn
Annual cashflow statement for LINCOLN PHARMACEUTICALS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 959 | 1,005 | 1,222 | 1,092 | 1,156 |
| Depreciation | |||||
| Non-Cash Items | -58.8 | -85.6 | -278 | -75.3 | -80 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -220 | -618 | -419 | -215 | -158 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 761 | 393 | 632 | 930 | 1,064 |
| Capital Expenditures | -455 | -143 | -396 | -192 | -260 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -326 | -224 | -177 | -597 | -724 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -781 | -366 | -573 | -789 | -984 |
| Financing Cash Flow Items | -10.4 | -13.5 | -12.7 | -18 | -6.57 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -25.6 | -45 | -51.8 | -64 | 1.59 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -45 | -18.8 | 6.95 | 76.7 | 81.1 |